What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Cancer Signs and Symptoms: Can Stem Cell Therapy Help?

Post by curncman »

Cancer Signs and Symptoms: Can Stem Cell Therapy Help?


curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Digital Transformation In Cell Therapy with Organicell Drs. Mari Mitrani & Michael Bellio

Post by curncman »

Digital Transformation In Cell Therapy with Organicell Drs. Mari Mitrani & Michael Bellio


curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

VJHemOnc – Video Journal of Hematological Oncology

Post by curncman »

VJHemOnc – Video Journal of Hematological Oncology

curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Investigating the effects of mechanical loading during development in 3D tissue engineered Bone

Post by curncman »

Investigating the effects of mechanical loading during development in 3D tissue engineered Bone

curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

How Cancer Spreads

Post by curncman »

How Cancer Spreads

curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Late Effects after a Transplant Using Donor Cells (Allogeneic Transplant)

Post by curncman »

Late Effects after a Transplant Using Donor Cells (Allogeneic Transplant)
Summary: Learn about medical complications that can develop months or years after a transplant using donor bone marrow, stem cells or cord blood. Learn how you can minimize the risk of developing problems and get appropriate treatment if a complication occurs.

Presenter: Catherine Lee MD, Assistant Professor of Medicine in Division of Hematology/BMT, Huntsman Cancer Institute, University of Utah Health

curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Oncotarget: Activating Interferons in AML

Post by curncman »

Oncotarget: Activating Interferons in AML



@Oncotarget published this trending research paper on April 27, 2021, entitled, “Activation of plasmacytoid dendritic cells promotes AML-cell fratricide,” by researchers from The Ohio State University.

Abstract:
Acute myeloid leukemia (AML) is characterized by the proliferation of immature myeloid blasts and a suppressed immune state. Interferons have been previously shown to aid in the clearance of AML cells. Type I interferons are produced primarily by plasmacytoid dendritic cells (pDCs). However, these cells exist in a quiescent state in AML. Because pDCs express TLR 7–9, we hypothesized that the TLR7/8 agonist R848 would be able to reprogram them toward a more active, IFN-producing phenotype. Consistent with this notion, we found that R848-treated pDCs from patients produced significantly elevated levels of IFNβ. In addition, they showed increased expression of the immune-stimulatory receptor CD40. We next tested whether IFNβ would influence antibody-mediated fratricide among AML cells, as our recent work showed that AML cells could undergo cell-to cell killing in the presence of the CD38 antibody daratumumab. We found that IFNβ treatment led to a significant, IRF9-dependent increase in CD38 expression and a subsequent increase in daratumumab-mediated cytotoxicity and decreased colony formation. These findings suggest that the tolerogenic phenotype of pDCs in AML can be reversed, and also demonstrate a possible means of enhancing endogenous Type I IFN production that would promote daratumumab-mediated clearance of AML cells.
curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021

Post by curncman »

Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021

https://finance.yahoo.com/news/gilead-k ... 00176.html

Wed, May 19, 2021, 5:00 PM EDT·6 min read


GILD
+1.24%
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate (ADC), as well as Kite’s chimeric antigen receptor (CAR) T-cell therapies across a range of cancers, including in existing indications and for investigational uses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/ ... 005762/en/

"Gilead-Kite Oncology is rapidly advancing transformative science for people facing historically difficult-to-treat cancers," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "Our first-in-class, TROP-2 directed ADC therapy is already having a meaningful impact for people with metastatic triple-negative breast and urothelial cancers, and data at ASCO will add further insight into its utility in TNBC in both monotherapy and future combination treatment approaches."
curncman
Posts: 1157
Joined: Fri Jun 26, 2020 8:27 am

Cancer Biotechs Are on the Move in Advance of Big Conference

Post by curncman »

Cancer Biotechs Are on the Move in Advance of Big Conference

https://finance.yahoo.com/m/6b995f43-d7 ... n-the.html

Image
Post Reply